Semax 30mg per vial

Semax is a synthetic analog of the adrenocorticotropic hormone 4-10 fragment (ACTH). This synthetic neuropeptide was initially developed in Russia in the 1980s to potentially prevent and treat circulatory disorders and acute cerebral hypoxia (caused by traumatic brain injury). 

While Semax is yet to be approved by the FDA, multiple studies have highlighted its potential. For example, Semax has been shown potential in improving memory, boosting mental clarity, and increasing dopamine levels in the brain. It might also possess neuroprotective properties. 

For instance, in a clinical trial involving 100 patients, Semax’s addition to conventional therapy expedited the restoration of damaged brain functions. In another trial, Semax showed promising potential to reduce overall brain damage and the risk of future strokes in patients with reduced brain blood flow.